Catalog mRNA products
Premade mRNAs to streamline your discovery
TriLink provides predesigned, readymade mRNAs as catalog products to use as controls in your R&D experiments and process development materials for downstream formulation in the development of mRNA vaccines and therapeutics. Our ready-to-use mRNAs contain 5′ CleanCap® cap analog (Cap 1), 5′ and 3′ UTRs, and 3′ poly(A) tail, resembling fully processed mRNAs ready for translation by the ribosome.
mRNAs manufactured with quality for robust performance
TriLink’s readymade RNAs are manufactured following our proprietary CleanScript™ in vitro transcription (IVT) method or the CleanCap® M6 protocol, reducing double-stranded RNA (dsRNA) levels and enhancing in vivo protein expression. The mRNAs are purified by DNase treatment, diafiltration, and oligo-dT capture to enrich full-length constructs while removing impurities and salts. To provide confidence in using our products, standard analytical tests are performed on our mRNAs and provided on certificates of analysis.
Those analyses include:
- Concentration determination by UV-Vis
- Construct integrity by gel and capillary electrophoreses
- Capping efficiency by capping assay
- dsRNA level by dot blot
Explore our readymade mRNAs
Reporter gene mRNAs
A variety of reporter mRNAs are available for tracking transfection efficiency and duration of expression in cultured cells or in vivo.
Genome editing mRNAs
Our mRNAs for genome engineering include Cas9, Cas9 nickase, and Cre recombinase.
Gene replacement mRNA
To model your secreted protein, we provide human erythropoietin (EPO) mRNA.
Antigen mRNAs
For delivering vaccine antigens, we provide mRNAs expressing the model antigen, ovalbumin (OVA).
Three mRNA designs for diverse projects
TriLink offers premade mRNAs in three designs: CleanCap® mRNAs, CleanCap® mRNAs (5moU), and CleanCap® M6 mRNAs (N1MePsU). They all contain an optimal 5′ Cap 1 found in higher eukaryotes for their functionality and stability. Their 5′ UTR is synthetic, containing a strong Kozak sequence, designed to promote efficient translation while the 3′ UTR is derived from mouse alpha-globin. Their key differences lie in the type of CleanCap® analog used and the base compositions, which may affect their protein expression and immunogenicity.
| CleanCap® mRNAs | CleanCap® mRNAs (5moU) | CleanCap® M6 mRNAs (N1MePsU) | |
|---|---|---|---|
| Expression system | Mammalian | Mammalian | Mammalian |
| 5′ cap | Cap 1 | Cap 1 | Cap 1 |
| Cap analog | CleanCap® AG | CleanCap® AG | CleanCap® M6 |
| 5′ and 3′ UTRs | Included | Included | Included |
| Poly(A) tail | 120 nt | 120 nt | 120 nt |
| Sequence composition | Unmodified uridines | Uridines substituted with 5-methoxyuridine | Uridines substituted with N1-methylpseudouridines |
| Protein expression | High | High | Highest |
| Immunogenicity | Normal | Reduced | Lowest |
| Browse products | Browse products | Browse products |
Related products and services
Contact us for a quote or more information about our premade mRNAs
Complete the form below and our Business Development team will contact you shortly.
